Jaguar Health (JAGX) Non-Current Deferred Tax Liability (2017 - 2019)
Jaguar Health (JAGX) posted quarterly Non-Current Deferred Tax Liability of $20594.0 for Q4 2019, down 97.92% quarter-over-quarter from $990549.0 in Q3 2017.
Jaguar Health (JAGX) Non-Current Deferred Tax Liability (2017 - 2019) Analysis & Trends
Jaguar Health (JAGX) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $20594.0 the latest figure, recorded in Q4 2019.
- In Q4 2019, Non-Current Deferred Tax Liability changed N/A year-over-year to $20594.0; the TTM figure through Dec 2019 stood at $20594.0 (changed N/A YoY), while the FY2019 annual figure was $20594.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability slipped to $20594.0 in Q4 2019 per JAGX's latest filing, from $990549.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $990549.0 in Q3 2017 and bottomed at $20594.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Jaguar Health | 447,549.24 | -9.62 Mn | 19.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 20,594.00 |
| Dec 31, 2019 | 20,594.00 |
| Sep 30, 2017 | 990,549.00 |
| Sep 30, 2017 | 990,549.00 |